Core Technology Laboratories, Asahi Quality and Innovations, Ltd., Moriya 302-0106, Japan.
Chiyoda Paramedical Care Clinic, Tokyo 101-0047, Japan.
Nutrients. 2024 Jul 10;16(14):2191. doi: 10.3390/nu16142191.
Probiotic-fermented milk is commonly used to maintain intestinal health. However, the effects of heat-treated fermented milk, which does not contain live microorganisms, on intestinal function are not yet fully understood. This study aimed to investigate whether heat-treated CP790-fermented milk affects fecal microbiota and gut health as a "postbiotic". A randomized, double-blind, placebo-controlled trial was conducted in healthy Japanese individuals aged 20-59 years with a tendency toward constipation. Participants consumed 100 mL of either the test beverage ( = 60) or placebo beverage ( = 60) for four weeks. The test beverages were prepared with heat-treated CP790-fermented milk, while the placebo beverages were prepared with nonfermented milk flavored with lactic acid. Fecal samples were analyzed using 16S rRNA gene sequencing. Constipation symptoms were assessed using defecation logs and the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire. Mood state was also assessed using the Profile of Mood States 2 (POMS2) questionnaire to explore its potential as a "psychobiotic". were significantly decreased by CP790-fermented milk intake. PICRUSt2 analysis predicted a decrease in the proportion of genes involved in the sulfate reduction pathway following the consumption of CP790-fermented milk. The CP790-fermented milk intervention significantly improved stool consistency and straining during defecation. These improvements were correlated with a decrease in . After the intervention, overall mood, expressed as total mood disturbance, and depression-dejection were significantly better in the CP790 group than in the placebo group. These results suggest that the intake of CP790-fermented milk could be effective in modulating gut microbiota and improving constipation symptoms and mood states.
益生菌发酵乳常用于维持肠道健康。然而,不含活菌的热处理发酵乳对肠道功能的影响尚未完全清楚。本研究旨在探讨热处理 CP790 发酵乳是否可以作为一种“后生元”来影响肠道菌群和肠道健康。一项随机、双盲、安慰剂对照试验在 20-59 岁有便秘倾向的健康日本成年人中进行。参与者连续四周每天饮用 100 毫升试验饮料(n=60)或安慰剂饮料(n=60)。试验饮料由热处理 CP790 发酵乳制备,而安慰剂饮料由添加乳酸调味的非发酵乳制备。使用 16S rRNA 基因测序分析粪便样本。通过排便日志和患者便秘症状评估问卷(PAC-SYM)评估便秘症状。使用心境状态问卷 2(POMS2)评估情绪状态,以探索其作为“心理生元”的潜力。CP790 发酵乳摄入可显著降低厚壁菌门和拟杆菌门的相对丰度。PICRUSt2 分析预测,CP790 发酵乳摄入后,参与硫酸盐还原途径的基因比例会减少。CP790 发酵乳干预可显著改善粪便稠度和排便时用力程度。这些改善与减少有关。干预后,CP790 组的总情绪困扰和抑郁-沮丧情绪明显优于安慰剂组。这些结果表明,CP790 发酵乳的摄入可能有效调节肠道菌群,改善便秘症状和情绪状态。